VivoSeq
Oncology

Neoplasms, Endometrial

6

Pipeline Programs↗

2

Active Trials↗

5

Companies Involved↗

Neoplasms, Endometrial is an early-stage landscape with 6 programs across 5 companies. The most active players are GSK, Teva, Pfizer. 6 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

31/100

Pipeline Velocity

11/100

Mech. Concentration

25/100

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

GSK logo

GSK

2 programs

Phase 3Teva logo

Teva

1 program

Phase 3Pfizer logo

Pfizer

1 program

Phase 3Incyte logo

Incyte

1 program

Phase 3Merck & Co. logo

Merck & Co.

1 program

Phase 3

Pipeline

Programs by Phase

Preclinical
No programs
Phase 1
No programs
Phase 2
No programs
Phase 36

Mocertatug Rezetecan

GSK

Paclitaxel

Teva

Doxorubicin

Pfizer

GSK5733584

GSK

Retifanlimab

Incyte

Approved
No programs

Analysis

Modality Breakdown

60%

Small molecule

3 of 5 classified programs — the dominant modality here.

40%ALL OTHERSMonoclonal antibody240%

Small molecule leads; the ring shows all 5 classified programs, each share of the total. Modality classified for 83% of 6 pipeline programs.

Analysis

Trial Status

2

clinical trials

Not yet recruiting1 · 50%
Recruiting1 · 50%

Clinical Trials

Trial Activity

A Randomized, Open-label, Multicenter, Phase 3 Study to Investigate GSK5733584 in Combination With Immune Checkpoint Inhibition for Maintenance Treatment of Participants With Mismatch Repair Proficient (MMRp) Endometrial Cancer
Not yet recruiting·GSK logoGSK·Phase 3·NCT07684599·610 enrolled
A Randomized, Open-label, Multicenter, Phase 3 Study to Investigate Mocertatug Rezetecan Compared With Chemotherapy in Participants With Endometrial Cancer After Platinum-based Chemotherapy and Immunotherapy
Recruiting·GSK logoGSK·Phase 3·NCT07286331·600 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)